Profile
ACST NVO VRTX REGN MRNA SGEN
Company Name Acasti Pharma Inc. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Moderna, Inc. Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $25.94M $564.36B $109.10B $105.53B $44.96B $43.15B
Employees 0.03K 66.02K 5.40K 13.68K 5.60K 3.26K
CEO Mr. Prashant Kohli Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. Stephane Bancel Mr. David R. Epstein B.Sc., M.B.A.
Ratings
ACST NVO VRTX REGN MRNA SGEN
Quant Rating Score 2 5 5 5 2 3
Quant Rating Sell Strong Buy Strong Buy Strong Buy Sell Neutral
Trading
ACST NVO VRTX REGN MRNA SGEN
Last Close $2.76 $128.42 $422.78 $973.8 $117.31 $228.74
High 52 $3.45 $199.54 $446.08 $993.35 $137.75 $228.9
Low 52 $0.47 $87.78 $323.57 $692.45 $69.51 $187.64
Price vs. 52 Week High -20 % -35.64 % -5.22 % -1.97 % -14.84 % -0.07 %
Price vs. 52 Week Low 487.23 % 46.3 % 30.66 % 40.63 % 68.77 % 21.9 %
Total Return
ACST NVO VRTX REGN MRNA SGEN
1 Month Return -18.94 % 3.14 % 6.61 % 7.64 % 11.58 % 0 %
3 Month Return 5.75 % 6.55 % 1.02 % 2.82 % 31.81 % 0 %
6 Month Return 24.12 % 26.91 % 13.15 % 21.89 % 67.47 % 7.03 %
9 Month Return 14.05 % -29.28 % 20.84 % 20.68 % 15.59 % 17.5 %
YTD Return -4.5 % 24.14 % 3.91 % 10.87 % 17.96 % 0 %
1 Year Return 486.98 % -25.02 % 21.69 % 30.83 % -9.27 % 14.94 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACST NVO VRTX REGN MRNA SGEN
Dividend Yield Percentage (TTM) - 0.16 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) -1696.38 % 1.1 % 8.49 % 6.2 % -3.65 % -3.35 %
Dividend Per Share (TTM) - 0.2 % - - - -
Payout Ratio (TTM) - 47.03 % - - - -
Growth
ACST NVO VRTX REGN MRNA SGEN
Asset Growth -38.48 % 30.35 % 25.23 % 13.23 % -28.74 % -1.21 %
Gross Profit Growth -234.56 % 32.32 % 9.25 % 6.49 % -85.12 % 22.93 %
Revenue Growth - 31.26 % 10.17 % 7.76 % -64.94 % 24.65 %
Revenue 3 Year - 90.51 % 59.87 % 55.67 % 2356.27 % 91.84 %
Revenue 5 Year - 124.2 % 218.58 % 110.3 % 1070.62 % 215.48 %
Revenue 10 Year -100 % 66.11 % 608.27 % 549.62 % 6447.35 % 494.04 %
EBIT Growth 200.86 % 37.11 % -12.94 % -14.6 % -145 % 10.13 %
Net Income Growth -332.11 % 50.71 % 8.96 % -8.87 % -156.37 % 9.51 %
Net Income 3 Yeari Growth Per Share 60.97 % 106.79 % 34.59 % 13.48 % -529.9 % -764.83 %
Net Income 5 Yeari Growth Per Share 26.38 % 133.86 % 70.33 % 74.02 % -160.17 % -276.93 %
Net Income 10 Yeari Growth Per Share 90.39 % 98.61 % 809.6 % 871.12 % -2046.03 % -624.16 %
Operating Income Growth 200.86 % 37.11 % -12.94 % -14.6 % -145 % 10.13 %
Operating Cash Flow Growth (CFG) 7.67 % 38.06 % -14.35 % -8.39 % -162.6 % 9.07 %
Operating 3 Year CFG 83.56 % 118.29 % 9.63 % 76.95 % -253.56 % -148.34 %
Operating 5 Year CFG 51.74 % 163.51 % 174.78 % 125.17 % -100.11 % -195.86 %
Operating 10 Year CFG 93.85 % 150.92 % 5187.08 % 713.56 % -4698.89 % -2622.09 %
EPS Growth -256.88 % 52.28 % 8.33 % -8.54 % -158.15 % 10.81 %
EPS Diluted Growth -256.88 % 52.37 % 8.35 % -9.03 % -161.39 % 10.81 %
Book Value Per Share -48.17 % 29 % 25.58 % 15.03 % -25.28 % -9.83 %
Share Holder 3 Year Equity Growth Per Share 23.94 % 75.22 % 104.06 % 137.56 % 439.94 % 33.92 %
Share Holder 5 Year Equity Growth Per Share 213.69 % 121.9 % 291.14 % 219.1 % 92.24 % 220.81 %
Share Holder 10 Year Equity Growth Per Share -94.63 % 49.62 % 1030.79 % 1286.9 % 1519.81 % 691.19 %
Dividend Per Share Growth - 26.89 % - - - -
Dividend 3 Year Growth Per Share - 64.4 % - - - -
Dividend 5 Year Growth Per Share - - - - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth 64.41 % 4.74 % 44.1 % 0.06 % 3.58 % -23.28 %
Free Cash Flow Growth 7.57 % 9.17 % -16.47 % -17.11 % -183.5 % 3.67 %
Updated On 31 Mar 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022
Profitability
ACST NVO VRTX REGN MRNA SGEN
Gross Profit Margin TTM 74075 % 84.65 % 86.86 % 87.16 % 21.77 % 75.4 %
Return on Assets TTM -51.48 % 29.87 % 16.81 % 11.22 % -35.67 % -20.64 %
Return on Equity TTM -59.56 % 91.82 % 23.61 % 15.15 % -41.83 % -28.06 %
Return on Capital Employed TTM 24.38 % 82.5 % 20.67 % 12.53 % -35.81 % -29.5 %
Net Income Per EBT TTM 80.72 % 79.81 % 84.31 % 95.44 % 124.28 % 101.53 %
EBT Per Ebit TTM -267.76 % 101.7 % 114.62 % 104.74 % 93.44 % 93.47 %
EBIT Per Revenue TTM -56706.25 % 45.03 % 40.85 % 29.46 % -99.69 % -34.37 %
Cash Flow To Debt Ratio TTM -56545.83 % 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Receivables Turnover TTM -0.03 3.87 5.68 2.51 13.32 3.64
Payables Turnover TTM 25.93 2.88 3.81 2.51 22.04 2.52
Inventory Turnover TTM - 1.12 1.65 0.62 13.67 1.07
Fixed Asset Turnover TTM -91.43 % 248.64 % 685.31 % 310.02 % 186.78 % 471.71 %
Asset Turnover TTM -0.04 % 81.71 % 42.57 % 38.12 % 30.81 % 63.3 %
Operating Cash Flow Per Share TTM -1.18 20.95 15.27 43.96 -7.54 -2.87
Free Cash Flow Per Share TTM -1.18 11.28 13.48 36.87 -9.61 -3.73
Cash Per Share TTM 218.26 % 208.61 % 3939.31 % 9758.35 % 2235.6 % 657.5 %
Operating Cash Flow Sales Ratio TTM 42409.38 % 38.24 % 38.74 % 36.17 % -55.91 % -23.48 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.06 % 53.85 % 88.22 % 83.87 % 127.41 % 129.82 %
Cash Flow Coverage Ratios TTM -56545.83 % 346.88 % 546.79 % 238.94 % -232.98 % -475.96 %
Price To Free Cash Flows Ratio TTM -1.91 77.7 31.36 26.55 -12.24 -61.54
Price To Operating Cash Flows Ratio TTM -2.34 42.47 27.68 22.15 -15.55 -79.67
Price Cash Flow Ratio TTM -2.34 42.47 27.68 22.15 -15.55 -79.67
Income Statement (TTM)
ACST NVO VRTX REGN MRNA SGEN
Revenue $0B $232.26B $9.84B $13.12B $6.75B $1.96B
Gross Profit $-0.05B $196.5B $8.58B $11.3B $2.06B $1.55B
Gross Profit Ratio 0% 84.6% 87.17% 86.16% 30.52% 79.1%
EBITDA $0.02B $112.94B $3.93B $5.13B $-3.21B $-0.62B
Net Income $-0.04B $83.68B $3.62B $3.95B $-4.71B $-0.61B
EPS Diluted -5.71 18.62 13.89 34.77 -12.34 -3.3
Balance Sheet (MRQ)
ACST NVO VRTX REGN MRNA SGEN
Long Term Debt $0B $20.53B $0.72B $2.7B $1.22B $0.04B
Total Liabilities $0.01B $207.93B $5.15B $7.11B $4.57B $0.87B
Total Equity $0.07B $106.56B $17.58B $25.97B $13.85B $2.8B
Total Investments $0B $17.5B $3.45B $13.51B $4.68B $1.42B
Total Debt $0B $27.01B $0.81B $2.7B $1.24B $0.04B
Total Assets $0.08B $314.49B $22.73B $33.08B $18.43B $3.67B
Cash Flow Statement (TTM)
ACST NVO VRTX REGN MRNA SGEN
Net Income $-0.04B $83.68B $3.62B $3.95B $-4.71B $-0.61B
Inventory $0B $-7.42B $-0.32B $-0.27B $0.75B $-0.23B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.02B $108.91B $3.54B $4.59B $-3.12B $-0.45B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.71B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 1.78
ABCL AbCellera Biologics Inc. 3.83
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.2
ABIO ARCA biopharma, Inc. 3.47
ABOS Acumen Pharmaceuticals, Inc. 3.36
ABSI Absci Corporation 4.91
ABUS Arbutus Biopharma Corporation 2.88
ABVC ABVC BioPharma, Inc. 1.06
ABVX Abivax SA American Depositary Shares 14.09
ACAD ACADIA Pharmaceuticals Inc. 15.25
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 1.47
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.9401
ACHV Achieve Life Sciences, Inc. 4.61
ACIU AC Immune SA 2.31
ACLX Arcellx, Inc. 49.74
ACRV Acrivon Therapeutics, Inc. Common Stock 8.77
ACXP Acurx Pharmaceuticals, Inc. 2.03
Unlock